Gliomas represent the most frequent form of primary brain tumors in adults, the prognosis of which remains extremely poor. Inactivating mutations on the tumor suppressor TP53 were proposed as a key etiological trigger of glioma development. p53 has been recently identified as a transcriptional target of parkin. Interestingly, somatic mutations on parkin have also been linked to glioma genesis. We examined the possibility that a disruption of a functional interaction between p53 and parkin could contribute to glioma development in samples devoid of somatic parkin mutations or genetic allele deletion. We show here that parkin levels inversely correlate to brain tumor grade and p53 levels in oligodendrogliomas, mixed gliomas and glioblastomas. We demonstrate that p53 levels negatively and positively correlate to bax and Bcl2 respectively, underlying a loss of p53 transcriptional activity in all types of glial tumors. Using various cell models lacking p53 or harboring either transcriptionally inactive or dominant negative p53, as well as in p53 knockout mice brain, we establish that p53 controls parkin promoter transactivation, mRNA and protein levels. Furthermore, we document an increase of parkin expression in mice brain after p53-bearing viral infection. Finally, both cancerrelated p53 inactivating mutations and deletion of a consensus p53 binding sequence located on parkin promoter abolish p53-mediated control of parkin transcription, demonstrating that p53 regulates parkin transcription via its DNA binding properties. In conclusion, our work delineates a functional interplay between mutated p53 and parkin in glioma genesis that is disrupted by cancer-linked pathogenic mutations. It also allows envisioning parkin as a novel biomarker of glioma biopsies enabling to follow the progression of this type of cancers.
INTRODUCTION
Gliomas accounts for a major therapeutic problem in neurooncology. They correspond to a large and heterogeneous variety of human brain tumors in which astrocytomas, regardless the grade of malignancy, are the more frequent forms, while oligodendrogliomas (OD) represent about 15 percent of glioma cases. The annual age-standardized incidence of primary malignant brain tumors is between B2.6-7 per 100 000 habitants worldwide. 1 Except some rare cases of radiotherapy-induced gliomas and mutation-associated Li-Fraumeni and Turcot diseases, their etiologies remain largely unknown.
Cell transformation is a result of a deregulation of normal proliferation, differentiation and apoptosis. Accordingly, a general characteristic shared by tumor cells concerns both loss of normal cell cycle control and disability to elicit cell death processes. Interestingly, the tumor suppressor p53 protein, when activated, blocks cell cycle and turns on programmed cell death pathway in order to force damaged cells to commit suicide. 2 Thus, p53, referred to as the 'guardian of the genome', is a crucial protector against tumor development. [3] [4] [5] This is supported by the widely reported observations that human cancers frequently harbor TP53 mutations inactivating its transcriptional activity 6 and by the fact that p53 has a key role in the initiation and progression of diffuse gliomas. [7] [8] [9] [10] It is therefore of utmost importance to elucidate the molecular cascades triggered by p53, and more particularly, to identify its downstream targets in order to delineate cancer-associated dysfunctions taking place during gliomas development.
Parkin has been proposed as an additional tumor suppressor and its levels are drastically lowered in various tumors. [11] [12] [13] [14] [15] These mutations lead to mitotic instability and abolishment of its canonical E3 ubiquitin-ligase activity. 16 It is noteworthy that besides its well-documented ubiquitinligase activity, we recently documented a new function of parkin as a transcriptional repressor of p53. 17 Thus, we established that parkin physically interacted with the TP53 promoter and that germline parkin mutations fully abolished parkin-mediated trans-repression of p53. 17 This set of data highlighted the possible molecular link between parkin expression, p53 control and tumorigenicity. We therefore questioned whether p53 could 1 Institut de Pharmacologie Molé culaire et Cellulaire, UMR7275 CNRS/UNSA, team labeled 'Fondation pour la Recherche Médicale' and 'Laboratory of Excellence (LABEX) Distalz', Valbonne, France; 2 control parkin expression and activity as part of a feed-back mechanism contributing to parkin-p53 homeostatic equilibrium and whether it could be altered in a pathological context.
We examined whether the loss of p53 transcriptional function triggered by cancer-related mutations, a common feature observed in tumors, 18 could alter parkin levels and, account at least partly for glioma development and aggravation. First, we analyzed the status of the expression of parkin and p53 in distinct types of brain tumors displaying various severity grades and we observed a clear inverse correlation between tumor grades and parkin levels, as well as an inverse relationship between parkin and p53. Second, we have investigated the molecular interplay between parkin and p53 in glioma and non-glioma cellular models harboring inactive, dominant negative or mutated p53, as well as in p53 knockout cells and mice brains. We demonstrate that decreased parkin promoter transactivation and protein levels result from loss of function of p53 transcriptional activity. Overall, our study unravels a feed-back mechanism involving a positive control of parkin by p53 that is impaired by p53 mutations, and thereby leads to decreased parkin expression and activity levels in such a pathological context. This functional interplay between parkin and p53 could contribute to glioma genesis and identifies parkin expression as a putative additional marker of progression in these types of brain cancers.
RESULTS
Parkin levels inversely correlate with tumor grade and p53 expression in brain tumors of distinct cell type origin We examined putative variations of parkin levels in pure OD and in oligoastrocytomas (OA, corresponding to mixed gliomas) harboring different severity grades from combined cohorts 1 and 2 (see Materials and methods). Figure 1 shows that parkin expression is reduced in grade II OD and that this reduction is even exacerbated in OD grade III (Figure 1a) . Interestingly, parkin levels are also dramatically reduced in OA grades II and III (Figure 1d Figure 1f ). Moreover, analysis of glioblastoma-derived samples (grade IV) indicates either a dramatic decrease of both parkin protein ( À 85.3 ± 8.2, Po0.0001, Figure 1g ) and mRNA levels ( À 86.3±16.3, Po0.0001, Figure 1h ) that is accompanied by an increase of p53 expression ( þ 125.9±35.2, Po0.01, Figure 1i ). It should be highlighted that in order to rule out any artifact that would arise from biological samples variability or grades evaluation of biopsies; we have examined the status of parkin and p53 proteins in cohorts 1 and 2 independently. Although the number of cases in cohort 2 was smaller, data analysis of the two cohorts fully corroborate the results obtained with pooled samples described in Figure 1 (data not shown).
To evaluate whether the increase of p53 levels could reflect the accumulation of a biologically inactive protein, we examined the status of Bax protein levels, a well characterized direct p53 transcriptional target, 19 as well as the expression of Bcl-2, which harbors a p53-responsive element, 20 which physically interacts with bax 21 and that is functionally connected to p53. 22 Bax and Bcl2 are two proapoptotic and prosurvival Bcl2 proteins family members 23 that are either directly or indirectly transcriptionally activated or repressed by p53, respectively. 19, 24 Figure 2 shows that the levels of Bax decreased with tumor grade in OD (R 2 ¼ 0.349, Po0.001, Figure 2a ) and OA (R 2 ¼ 0.327, Po0.001, Figure 2c ) while Bcl2 expression analysis in the same samples reveals an augmentation of Bcl2 protein expression in both OD (R 2 ¼ 0.31, Po0.05, Figure 2e ) and OA (R 2 ¼ 0.230, Po0.01, Figure 2g ). Thus, the modulations of Bax and Bcl2 expressions suggested a functional inactivation of p53 transcriptional activity. This was supported by the correlation analysis of Bax and Bcl2 protein levels with p53 levels that indicate a linear negative correlation between Bax and p53 in OD (R 2 ¼ 0.919, Figure 2b ) and OA (R 2 ¼ 0.860, Figure 2d ) and a positive relationship between Bcl2 and p53 in OD (R 2 ¼ 0.999, Figure 2f ) and OA (R 2 ¼ 0.884, Figure 2h ). Again, analysis of glioblastoma biopsies indicates either a decrease of bax ( À 92.7±7, Po0.001, Figure 2i ) and an increase of Bcl2 ( þ 120.1 ± 30, Po0.05, Figure 2j ) expression. This data clearly indicate a loss of function of p53-mediated control of Bax and Bcl2 in gliomas and suggest that tumors development, at least partly, results in the accumulation of transcriptionally inactive p53. This agrees well with previous studies showing that frequent mutations associated with p53 trigger a loss of function of the protein in gliomas. 25, 26 We therefore questioned whether p53 could act as a modulator of parkin promoter transactivation and whether p53 loss of function occurring in glioma could ultimately account for early and grade-dependent reduction of parkin observed in these tumors.
Parkin expression is decreased in various tumor types linked to p53 mutations Recent studies indicated that parkin could be under-expressed in tumors due to either gene deletion or presence of somatic mutations. 16, 27 Thus, in order to exclude the possibility that the decrease in parkin expression described in Figure 1 was artifactually due to parkin gene deletion or metabolic instability resulting from PARK2 missense mutations, 28 we have analyzed both PARK2 and TP53 genetic status and mutation profile. We have found 4 out of 54 samples displaying an allele deletion and all other samples were wild-type PARK2 (Table 1) . Furthermore, all parkin mutations identified correspond to constitutional mutations (polymorphism) as they were also present in the plasma DNA from the same patients and therefore do not affect overall parkin structure/levels. The sequencing of samples also allowed us to identify those bearing a mutated p53 (Table 1) and to establish the proportions of mutated TP53-linked tumor within subgroups. About 20-40% of the samples harbor a p53 mutant protein ( Table 2 ). It should be noted that, according to the MUT-TP53 2.0 matrix allowing predicting the transcriptional activity status of mutant p53, 29, 30 all mutations were considered as fully inactivating except those found at positions 90, 15 and 138 (see Supplementary Table 2 ). However, in the latter cases, an additional inactivating mutation was found to be present on TP53 gene (see mutations 175, 234 and 245 in biopsies no. 1237, 1241 and 1324, respectively in Supplementary Table 2 ). The above set of data led us to examine the expression levels of parkin (samples harboring an allele deletion have been omitted) in TP53-mutated tumors. Figure 3 shows first that the omission of samples, in which parkin had been deleted does not modify the grade-dependent decrease of parkin expression in tumors harboring either wild-type or mutated TP53 (Figure 3a) . Interestingly, this grade-dependent reduction was still observed when only samples harboring a TP53 mutation were considered (Figure 3b) . Accordingly, the examination of Bax and Bcl-2 expressions in mutated p53-containing samples only, confirmed the grade-dependent modulation of the expression of these proteins (Figures 3c and d) . Figure 4 shows that parkin levels are grade-dependently reduced in all tumor types. Overall, the above set of data confirms the drastic reductions of parkin levels in all tumor types associated with a TP53 mutation and suggest a direct link between parkin expression and tumor grades.
Cancer-associated TP53 mutations or p53 dominant negative trigger reductions of parkin protein levels and promoter transactivation Parkin depletion and p53 accumulation could be seen as concomitant but unrelated events occurring in glioma. Alternatively, one could envision that the loss of function of p53 documented above could account for parkin depletion. In this context, we examined the status of parkin protein in various human glioblastoma cell lines (GL15, 42MG, 8MG), in which the presence of TP53 mutations has been characterized [31] [32] [33] (see Supplementary Table 3 ) and the SH-SY5Y 32 human neuroblastoma cell line expressing wild-type p53 as a reference cell type. First, it should be noted that glioblastoma cell lines mimic pathological brain biopsies in that they also express high levels of p53 (Figures 5a and b) . In these cells, p53 is biologically inert as it appears unable to yield luciferase activity from a construct (PG13, 34 ), in which luciferase reporter gene was under the control of a canonical p53 responsive element (Figure 5c ). Conversely, SH-SY5Y that harbors endogenous wild-type p53 expresses low levels of p53 in basal conditions ( Figure 5a ) and as corollary exhibit remarkable p53 activity (Figure 5c ). Of most interest, unlike SH-SY5Y, glioblastoma cell lines display very low levels of parkin protein and mRNA levels (Figures 5d-f) . Therefore, one can conclude from the above set of data that p53 inactivation by mutations in glioblastoma cells leads to enhancement of p53-like immunoreactivity and concomitantly yields low levels of parkin. Again, this data argues in favor of a p53 loss of functionassociated downregulation of parkin mRNA and protein levels. To definitely confirm this conclusion, we assessed the ability of wild-type and mutated p53 to modulate parkin expression and promoter transactivation. SH-SY5Y were transiently transfected with empty vector or p53 complementary DNA (cDNA) constructs either wild-type or harboring the R175H or the R273H mutation. It should be noted that the R273H mutation is the one occurring in the 8-MG glioblastoma cell line studied in Figure 5 . 31 Figure 3 indicates that both parkin protein levels ( Figure 5g ) and promoter transactivation ( Figure 5h ) were increased by the overexpression of wild-type p53 cDNA while p53 mutations fully abolished p53-associated increases of parkin protein and promoter transactivation. Finally, we have taken advantage of a cell model, in which an inactive dominant-negative p53 is overexpressed (MCF7-DD p53, see Materials and methods) to further confirm that the transcriptional inactivation of p53 leads to a diminution of parkin expression ( À 44.8 ± 15.8, n ¼ 4, Po0.05, Figure 5i ). The above set of data shows that one of the physiological roles of p53 is likely to transcriptionally upregulate parkin protein and suggests that TP53 mutations abolish this function, thereby leading to a cellular deficit of parkin.
p53 deletion triggers reduction of parkin protein and mRNA levels in cells and in mice brain As a complementary approach, we have examined the impact of endogenous p53 on parkin protein, promoter activity and mRNA levels in two distinct cell types, in which p53 had been invalidated. p53 deficiency in Human Colorectal adenocarcinoma (HCT116-Dp53) leads to a decrease of parkin expression ( À 69.7% ± 7.9 versus HCT116 control cells, Po0.001, Figure 6a ). We also compared mouse fibroblasts, in which either p19
Arf À 1 or p19
Arf À 1 and p53 had been deleted. 35 First, interestingly, the depletion of endogenous p53 leads to decreased parkin promoter transactivation and mRNA levels ( À 94, 4%, n ¼ 6, Po0,01, Figure 6b and À 74.0% ± 20.8, Po0.01, Figure 6c ; compare lanes ( À ) of black and empty bars). As it was shown in SH-SY5Y (see Figures 5g and h) , complementation experiments by wild-type p53 cDNA transfection rescues parkin promoter activation in both p19
Arf À 1 À / À and p19 Arf À 1 À / À p53 À / À fibroblasts (compare lanes ( À ) and ( þ ) for black and white bars in Figure 6b ), an observation corroborated by increased levels of parkin mRNA (Figure 6c ). This data confirm the positive control of parkin by p53 and importantly shows that this conclusion is not cell specific and stands for both endogenous and overexpressed wild-type p53.
In order to establish whether p53-dependent control of parkin also takes place in vivo, we have first investigated the status of parkin in wild-type and p53-knockout mice brain. We have observed a reduction of both parkin expression ( À 42.0%±9.5, n ¼ 5, Po0.05, Figure 7a ) and mRNA ( À 65.0% ± 22.0, n ¼ 5, Po0.05, Figure 7b ) levels. Importantly, we establish that p53-viral infection increases parkin protein expression and mRNA levels in mice brain (Figure 8 ). Thus endogenous and overexpressed p53 both upregulate parkin protein and mRNA levels, in vivo. Figure 2) . The fact that parkin promoter transactivation was also impaired by p53 mutations led us to envision that parkin could behave as a direct transcriptional target of p53. This hypothesis is supported by the fact that the two mutations shown to abolish p53-associated increase of parkin protein and mRNA (see data in Figures 5f-h) have been described as hot spot p53 glioma-associated mutations that are known to abolish p53 DNA binding properties (for review see Brosh and Rotter 36 ). On the basis of this assumption, we have performed an in silico study of the human parkin promoter and we have identified a probable p53 consensus motif (Figure 9a) . We have deleted part of this sequence from the parkin promoter (Figure 9a ) and analyzed the impact of p53 overexpression on wild-type (Wt-hPK) or p53-deleted (D-hPK) parkin promoter activities. As would have been predicted, the overexpression of wild-type p53 leads to an upregulation of the wild-type parkin promoter activity ( þ 640.2 ± 34.5, Po0.0001, Figure 9b ), a feature fully abrogated by the deletion of the p53-responsive element (D-hPK, Figure 9b ). Altogether, these data definitely demonstrates that p53 controls parkin transcription via its interaction with parkin promoter. This agrees well with a recent study by Zhang et al. 37 that shows that p53 physically interacts with parkin promoter by ChIP analysis.
DISCUSSION
Several theoretical and experimental grounds suggested that parkin could contribute to cancers etiology. Thus, parkin gene is located at a well-defined locus of chromosomal instability, FRA6, and was deleted in both breast and ovarian cancers and two lung adenocarcinoma cell lines. 12 Lentivirus-induced expression of parkin leads to decreased tumorigenicity of parkin-deficient lung cancer cells in mice 38 and its epigenetic downregulation has been associated to acute lymphoblastic leukemia and chronic myeloid leukemia. 39 Interestingly, a recent paper by Veeriah et al. 16 showed that somatic mutations of the parkin gene are associated to glioblastoma and other human malignancies. Noteworthy, the above-cited somatic mutations lead to mitotic instability and abolishment of the E3-ubiquitin ligase activity parkin canonical function. 40 The above set of data led to the proposal that parkin could act as a tumor suppressor.
p53 is also a tumor suppressor, the mutations on which trigger various types of tumors. 25 Indeed, most tumors show a drastic increase in the levels of loss of function of p53 mutants and p53 accumulation is often predictive of p53 mutations. 25, 26 Our analysis of p53 mutations and expression levels in OD, OA and secondary glioblastomas indicated about 20-50% of samples bearing a p53 mutation revealed a grade-dependent accumulation of p53 protein levels (see Figure 1 ) in agreement with several works based on immunohistochemical approaches. [41] [42] [43] Why do mutant p53 levels increase in tumors? Several studies indicated that this could be due to the impairment of its ubiquitination and subsequent degradation by the proteasomal machinery. 44 Mdm2 has been described as a key ubiquitin-ligase Parkin and p53 interplay in glioma development J Viotti et al involved in the ubiquitination and degradation of p53 by the proteasome. 45 Interestingly, as Mdm2 retains its ability to degrade mutated p53, it has been suggested that the accumulation of p53 is the consequence of its incapability to transactivate Mdm2. 46 However, this mechanism is likely not ubiquitous and one can envision alternative pathways leading to mutated p53 accumulation.
We have recently shown a novel function of parkin as transcription repressor of p53. 17 Thus, we established that parkin physically interacted with the p53 promoter and that germline PD-associated parkin mutations fully abolished parkin-mediated trans-repression of p53, 17 suggesting a possible molecular connection between parkin expression, p53 control and tumorigenicity. This led us to examine the status of parkin expression in glioma, the putative correlation between parkin and p53 levels according to tumor grades and the functional interplay between these two proteins that could explain the modulation of their expression during gliomas progression.
In the present study, we first establish that parkin protein and mRNA levels are decreased as tumor grades increase. That this observation stands for two independent cohorts is not anecdotic as biological tissue variability, technical aspects such as surgical acts to remove biopsies and immunohistological assessment of tumors could bring uncertainty in grade classification. Of most interest, parkin levels inversely correlate with p53 expression (see Figure 1 ), particularly in those cases where samples harbor a p53 mutation (Figures 3 and 4) . This biochemical correlation did not per se indicate that the two events were directly correlated. In order to confirm a functional link between the two proteins, we have examined whether p53 could modulate parkin at a transcriptional level. This was motivated by the fact that most of cancer-associated mutations of p53 are associated to a loss of its transcriptional activity. 47 This statement was comforted in our study by the observation that the expressions of two direct and indirect p53 transcriptional targets, Bax and Bcl2, were respectively, negatively and positively correlated with p53 expression according to tumor grade (see Figure 2) , thereby confirming p53 loss of DNA binding activity in these tumors. Moreover, we show that in three distinct human glioma cell lines (GL15, 8MG and 42MG), high levels of p53 accompany low expressions of parkin, a phenotype totally opposite to the one observed in SH-SY5Y cells. Thus, human glioma cell lines expressions of parkin and p53 mimic that observed in highgrades biopsies and therefore, appear as relevant models to study putative p53-mediated control of parkin transcription and expression. The above data are in full agreement with a study that established decreased levels of parkin in gliomas, and which shows an inverse relationship between parkin function and glioma-related mortality. 48 We demonstrate here that p53 controls parkin promoter transactivation. This conclusion stands in five independent lines of data. First, parkin protein levels and promoter transactivation were enhanced by wild-type p53 overexpression, the mutations on which abolish this phenotype. Second, the depletion of endogenous p53 in two distinct cell lines triggers reductions of parkin expression, promoter transactivation and mRNA levels. Third, a cell line expressing a p53 dominant-negative also displays lowered parkin expression. Fourth, ablation of a putative consensus binding sequence targeted by p53 on parkin promoter fully blocks p53-associated increase of parkin promoter transactivation. Fifth, importantly, our data show that parkin protein and mRNA levels are reduced in p53-knockout mice and increased after p53 viral infection in mice brain. Altogether, our data undoubtedly demonstrate that p53 positively controls parkin promoter transcription in vitro and in vivo and that cancerassociated mutations on p53 impair this control and likely contribute to lowering parkin expression along with tumor progression. This agrees well with a recent study showing that human parkin gene indeed behaved as a transcriptional target of p53 that directly binds to parkin gene. 37 Parkin expression is often reduced in tumors and our data demonstrate that this can be accounted for by decreased p53-mediated transcriptional control. It is striking that conversely, p53 augmentation in tumors could, at least in part, be due to reduced parkin expression. Thus, we have recently demonstrated that parkin acts as a direct transcriptional repressor of p53. 17 It is therefore tempting to envision a functional interplay between parkin and p53 ( Figure 10) . In physiological conditions, parkin lowers wild-type p53 and thereby, lowers its own production. This feed-back mechanism likely contributes to maintain a cellular homeostasis between parkin and p53. In tumors, transcriptionally inactive mutated p53 would lose its capacity to upregulate parkin promoter transcription, thereby explaining reduced levels of parkin protein. Accordingly, lowered parkin levels would therefore lead to reduced trans-repression of p53 explaining the accumulation of mutated p53. This cross-talk would feed a vicious cycle, by which tumorigenicity could progress.
This reduction of the tumor suppressive function of parkin and its functional dialog with p53 identifies parkin as a key molecular player in glioma biology, but also a new grade-related biopsy biomarker and our study may delineate new potential tracks to pharmacologically interfere with glioma progression.
MATERIALS AND METHODS
Mouse Embryonic Fibroblasts (MEF), Human Colorectal adenocarcinoma (HCT116), SH-SY5Y human neuroblastoma, the human breast cancer (MCF-7) and the human (42MG, GL15, 8MG) glioma cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin (50 mg/ml) in 5% CO 2 . Immortalized mouse embryonic fibroblasts invalidated for the p53 Figure 5 . Dominant negative or cancer-related mutations of p53 abolish its ability to regulate parkin protein levels and promoter transactivation. (a-e) illustrate p53 (a, b) or parkin (d, e) protein levels, p53 transcriptional activity (c) and parkin mRNA levels (f ) measured in the indicated glioblastoma (GL15, 8MG or 42MG) or neuroblastoma (SH-SY5Y, SH) cell lines, by western blot and PG13 analysis as described in Materials and methods. (g, h) show the effect of overexpressed empty vector (EV), wild-type (WT) and mutated (R175H, (175) and R273H, (273)) p53 constructs on parkin protein levels (g) and promoter activity (h) in SH-SY5Y cells. (i) shows parkin protein levels in MCF-7 cells expressing (MCF-7-DDp53, white bars) or not (MCF7-wt, black bars) a dominant negative truncated p53. Quantifications correspond to parkin densitometric analyses normalized by actin protein charge loading control. Bars are the means ± s.e.m. of 4-6 independent determinations (two independent experiments performed in duplicate or triplicates). *Po0.05; **Po0.01; ***Po0.001; ns, not statistically significant. and p53/p19
arf genes 35 or MCF-7 cells 11 expressing either wild-type or a dominant negative truncated p53 mutant, were provided by Drs Roussel and Bourdon, respectively. Transient transfection of SH-SY5Y and mouse fibroblasts (MEF), were respectively carried by means of either lipofectamine 2000 (Invitrogen, Saint Aubin, France) or Nucleofactor kit (Amaxa Biosystems, Basel, Switzerland) according to the manufacturer's instructions as previously described. 49 
Constructs
The wild-type 154 bases human parkin promoter construct provided by Dr West (Johns Hopkins University Scholl of Medicine, Baltimore, USA) has been previously described. 50 The deletion of the À 42 to À 45 nucleotides region on the wild-type human parkin promoter that constitutes the core p53 putative binding site (located between nucleotides À 48 to À 41, considering as þ 1 the A of the start codon) was performed by site-directed mutagenesis kit (QuikChange II, Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The primers used were: forward hprPKdelp53-S (5 0 -GCGCCGCTGCGCGGGCCTGTTCCTGGCCCG-3 0 ) and reverse hprPKdelp53-AS (5 0 -CGGGCCAGGAACAGGCCCGCGCAGCGGCGC-3 0 ).
A BamHI/XbaI fragment containing the human p53 coding sequence and a flag tag sequence has been subcloned in the pCDNA3.1 ( þ ) from Invitrogen. The p53 R175H and R273H mutants were obtained by sitedirected mutagenesis of the p53-pcDNA3.1 ( þ ) flag tag construct. We used the forward p53R175H-S (5 0 -CGGAGGTTGTGAGGCACTGCCCCCACCA TGAGC-3 0 ) and the reverse p53R175H-AS (5 0 -GCTCATGGTGGGGGCAGTGCC TCACAACCTCCG-3 0 ) primers to obtain the R175H mutant and the forward p53R273H-S (5 0 -CGGAACAGCTTTGAGGTGCATGTTTGTGCCTGTCCTGGG-3 0 ) and reverse p53R273H-AS (5 0 -CCCAGGACAGGCACAAACATGCACCTCAAAG CTGTTCCG-3 0 ) primers for the R273H mutant.
Patient samples
Cohort1. Human samples were gathered by the tumor bank of the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniè re, Groupe Hospitalier Pitié -Salpê triè re UMRS 975, Paris, France. Fifty-four patients who underwent a craniotomy for tumor resection were included in this retrospective study concerning the 2004-2012 period. Only patients satisfying the following inclusion criteria were kept for our study: minimal age of onset of 18-years-old, diagnosis of gliomas according to the WHO criteria and available clinical data. This cohort includes 18 grade II (9 oligodendrogliomas, 8 mixedgliomas and 1 astrocytoma), 20 grade III (6 OD, 13 mixed gliomas and 1 astrocytoma), 16 grade IV (10 glioblastoma and 6 mixed glioblastoma) and 10 control (non-related epilepsy surgery-derived samples) groups. Tumor samples were snap-frozen and stored at À 80 1C immediately after surgical resection. High-molecular weight DNA was isolated from both tumor and peripheral blood using a standard phenol-chloroform procedure. A written informed consent from all patients and validation by a local ethical committee were obtained for this study allowing molecular, genetic 
À / À (white bars) fibroblasts after transient transfection with either empty vector ( À ) or p53 cDNA ( þ ). Bars are the means ± s.e.m. of six independent determinations (three independent experiments performed in duplicates). *Po0.05; **Po0.01; ***Po0.001; ns, not statistically significant. Eighteen patients submitted to a craniotomy for tumor resection were included in this retrospective study concerning the 1992-2011 period.
The patient's inclusion criteria and ethical procedures those described for cohort1. This cohort included six samples per tumor grade (II, III) OD, six grade IV (glioblastoma) and four controls non-related epilepsy surgeryderived samples.
Western blot analyses
Proteins (50 mg for biopsies and cell homogenate samples and 100 mg for mice brain samples) were separated on 12% SDS-polyacrylamide gel electrophoresis gels and wet-transferred to Hybond-C (Amersham Life Science, Buckinghamshire, UK) membranes. Then, samples were immunoblotted using mouse monoclonal anti-parkin (MAB5512, Chemicon, Billerica, MA, USA), anti-flag (Sigma, Lyon, France) and anti-Bcl2 (SC7382, Santa Cruz, Heidelberg, Germany) antibodies or with rabbit polyclonal antip53, (CM1 provided by JC Bourdon) and anti-bax (6A7, Pharmingen, Figure 8 . Viral overexpression of p53 triggers increased protein and mRNA levels of parkin in mice brain. Mice were injected bilaterally with control (eGFP adenovirus) and p53 viruses (107 PFU in each hemisphere). Ten days after infection, the two halves of the brains were processed for either protein (a) or mRNA (b) expressions as described in the Materials and methods. Bars represent the relative concentration of parkin protein or mRNA levels expressed as the percent of control mock-infected mice brain (taken as 100) and are the means±s.e.m. of five brains. *Po0.05. In normal conditions, that is, when both parkin and p53 are wild-type proteins, several cellular challenges such as stress leads to transient increased levels of p53 allowing the protein to trigger its stress-related phenotypes. Concomitantly, this increase in wild-type p53 leads to increased levels of parkin (Zhang et al. 37 and present study). As a consequence, increased parkin triggers transcriptional repression of p53, 17 allowing restoring p53 normal levels. Thus, parkin and p53 interplay contributes to the regulation of parkin/p53 homeostasis in normal conditions. In cancer-related conditions linked to p53 mutations, the abolishment of p53 transcriptional activity leads to a drastic reduction of parkin. These lower levels of parkin trigger enhanced expression of mutated inactive p53. This may explain the inverse correlation existing between the expression levels of parkin and p53 in glioma tumors.
Franklin lakes, NJ, USA) antibodies. Immunological complexes were revealed with either anti-rabbit or anti-mouse IgG-coupled peroxidase antibody (Jackson Immunoresearch, Cambridgeshire, UK) by electrochemiluminescence detection method (Roche Diagnostics, Meyland, France). Chemiluminescence was recorded using a luminescence image analyzer LAS-3000 (Raytest, Fuji, Asniè res, France), and quantification of nonsaturated images were performed using the FUJI FILM Multi Gauge image analyzer software.
Real-time PCR analysis of parkin mRNAs in cells and mice brains RNA from cells and mice brains or human biopsies were extracted using the NucleoSpin RNA II or the RNeasy kit, respectively following manufacturer's instructions. After DNAse treatment, total RNA was reverse transcribed (AMV-transcriptase, Promega, Madison, WI, USA) then subjected to real-time PCR by means of a Rotor-Gene6000 apparatus (Qiagen, Hilden, Germany), using the SYBR Green detection protocol. 
Stereotaxy and viral injection
Adult females C57Bl/6 (P90) were deeply anesthetized with ketamine (100 mg/kg body weight; Ketamine 1000; Ceva, Bruxelles, Belgique) and xylazine (10 mg/kg body weight; Rompun 2%; Centravet, Plancoet, France) dissolved in 0.9% sterile saline and positioned in a stereotaxic frame. Animals of each group (control and wild-type p53) were injected bilaterally into the striatum, using appropriate coordinates (1 mm anterior to the bregma, 2 mm lateral and 3 mm deep from the skull surface) with either eGFP adenovirus or adenovirus expressing human p53 and GFP (10 7 PFU in each hemisphere; Vector Biolabs, Philadelphia, PA, USA). Animals were killed 3, 7 and 14 days after injection. Proteins and mRNA were extracted from whole brains and analyzed as described above.
p53 activity and parkin promoter transactivation The p53 transcriptional activity, wild-type or mutated parkin promoter transactivation (see constructs section) were measured as described 51 after co-transfection of 0, 5-1 mg of the above cDNAs and 0, 2-0, 5 mg of b-galactosidase cDNA in order to normalize transfection efficiencies as described. 51 Luminescence was measured as reported. 19 1 Mb genomic bacterial artificial chromosome ARRAY-CGH A full-coverage genomic bacterial artificial chromosome aCGH with an average resolution of 1 Mb, previously described, 52 was used for DNA copy number analysis. The procedures for DNAs extraction, hybridization and washing have been described previously. 53 Arrays were scanned using a 4000B scan (Axon, Union City, CA, USA). Image analysis was performed with Genepix 5.1 software (Axon, Union city, CA, USA) and ratios of Cy5/ Cy3 signals were determined. The ratio of Cy5/Cy3 of the bacterial artificial chromosome including or contiguous to the target gene investigated was attributed to the genes of interest. A ratio above at least 3.0 was fixed as the threshold to conclude that a gene amplification occurred. Data were normalized with microarray normalization MANOR, bacterial artificial chromosome status (gained, lost, amplified or normal) was determined using GLAD (Applied Optic Research, Woodland, WA, USA), and the final results were visualized with VAMP software (Woods Hole, MA, USA).
Mutation analysis of PARK2 and TP53
All PARK2 and TP53 coding exons of all tumor and paired-blood plasma DNAs were analyzed by Universal tailed amplicon sequencing approach (454 Sequencing Technology, Roche) and confirmed by direct genomic sequencing of both DNA strands by Sanger's method. In brief, the Universal tailed amplicon sequencing with 454 GS Junior system implies a initial PCR amplification (using primers detailed in Supplementary Table S1 and amplification conditions available upon request) of high-molecular weight DNA extracted using standard phenol-chloroform procedures, a second PCR aiming MID (multiplex identifier) and 454 adapters incorporation, an emulsion PCR step launched according to the emPCR Amplification Method Manual Lib-A protocol (GS Junior Titanium Series, Roche) and enrichment and pyrosequencing according to the Sequencing Method Manual (Roche). Mutations found with GS Junior were validated by Sanger sequencing method. To make sure of the somatic characteristic of each alteration and avoid polymorphisms, the constitutional DNA of each patient was also tested with Sanger. After amplification, PCR products were purified conforming to the Agencourt AMPure XP PCR purification protocol (Beckman Coulter, Villepinte, France) with the Biomek NX Automation Workstation. Sequencing reactions were performed in both directions using the Big-Dye Terminator Cycle Sequencing Ready Reaction (Applied Biosystems, Courtaboeuf, France). Extension products were purified with the Agencourt CleanSEQ protocol according to manufacturer's instructions (Beckman Coulter). Purified sequences were analyzed on an ABI Prism 3730 DNA Analyzer (Applied Biosystems). Forward and reverse sequences were systematically analyzed.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (www.graphpad.com version 4.00 for Windows, Software, San Diego CA USA) by using either the Student's t-test or one-way ANOVA with Newmann-Keuls's and linear trend post hoc tests. Correlation analysis was performed by means of the Pearson test (Pearson r and P-value determinations) Significant differences are: *Po0.05; **Po0.01; ***Po0.001.
